Loading patent…
AssigneeUniversidad de Sevilla
InventorsCarolina Sousa Martin, Isabel Comino Montilla, Ana Real Calderon, Santiago Vivas Alegre, Angel Cebolla Rammirez
Estimating the term…
The present invention, fitted in the medical-clinical sector, shows a method for monitoring the ingestion of gluten by measuring protein/gluten peptides present in fecal samples with antibodies against immunogenic peptides resistant to gastrointestinal digestion. The presence or absence of said immunogenic peptides is controlled by immunological assays based on reactive antibodies against immunogenic gluten peptides that are resistant to proteolysis. These assays may be quantitative techniques as ELISAs, or qualitative as rapid immunochromatographic assays, immunoblots, etc. These measures may also be applied to verify compliance with the gluten-free diet, to improve diagnosis in cases of refractory or severe symptoms of celiac disease, in cases in which a gluten-free diet is supposedly being respected, or to clinical research on the effectiveness of enzymatic therapies related with prolamin detoxification.
A process for monitoring ingested gluten in an individual comprising detecting immunotoxic peptides in fecal samples by immunological methods using antibodies that recognize peptides from gluten proteins resistant to gastrointestinal digestion.
(canceled)
A process for monitoring the compliance with gluten-free diet comprising detecting immunotoxic peptides in fecal samples by immunological methods using antibodies that recognize peptides from gluten proteins resistant to gastrointestinal digestion, wherein the detection of immunogenic peptides in said samples indicate the non-compliance of the individual with the gluten-free diet.
A process for detecting the uncontrolled intake of gluten in celiac patients following a gluten-free diet but with refractory and acute symptoms of celiac disease comprising detecting immunotoxic peptides in fecal samples by immunological methods using antibodies that recognize peptides from gluten proteins resistant to gastrointestinal digestion, wherein the detection of immunogenic peptides in said samples indicate the uncontrolled intake of gluten in celiac patients.
A process for monitoring the effectiveness of therapies related to the elimination of immunogenic peptides of gluten comprising detecting immunotoxic peptides in fecal samples by immunological methods using antibodies that recognize peptides from gluten proteins resistant to gastrointestinal digestion, wherein the detection of immunogenic peptides in said samples indicate that the therapies are effective.
An analytical kit for detecting immunogenic gluten peptides in feces containing:
Dependencies are inferred from the claim text.